Targeting a specific protein in blood stem cells to improve treatment for myelofibrosis
Official title: Targeting beta1 integrin in JAK2V617F+ stem cells
Funded at Boston University Medical Campus · NIH-10754908 · Data updated 2026-11-12
This study is looking at new ways to treat primary myelofibrosis, a type of blood cancer, by focusing on stubborn stem cells that don’t respond well to current treatments, and it aims to find out if blocking a specific protein can make existing therapies work better for patients like you.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 15, 2022 |
| Project end | November 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $123,750 |
| NIH project number | 5R03OD031959-02 |
| Project ID | NIH-10754908 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have been diagnosed with primary myelofibrosis or related myeloproliferative neoplasms.
✕Less likely to help
Patients who do not have the JAK2V617F mutation or those with other types of blood cancers may not benefit from this research.
What this research studies
This research focuses on improving treatments for primary myelofibrosis, a type of blood cancer, by targeting JAK2V617F+ stem cells that are resistant to current therapies. The study investigates the role of beta1 integrin, a protein that helps maintain these stem cells, and aims to develop new treatments that can effectively eliminate them. By using mouse models and patient data, the researchers will explore how inhibiting beta1 integrin can enhance the effectiveness of existing therapies. This approach could lead to better long-term outcomes for patients suffering from this condition.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with primary myelofibrosis, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in blood cancers, suggesting that this approach could be effective.
Where this research is happening
-
Boston University Medical Campus
Boston, United States Active
Researchers
- Principal investigator: Matsuura, Shinobu — Boston University Medical Campus
- Study coordinator: Matsuura, Shinobu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.